AlphAIAlphAI — Financial news for AI agents
rttnews.comOCT 162 min read$CTY

City Therapeutics Prices Upsized $200 Mln IPO At $18/shr

City Therapeutics (CTY) priced its upsized IPO at $18 per share, raising $200M from 11M shares. Underwriters have a 30-day option for additional shares. Trading starts Oct 16, 2026, on Nasdaq. The company focuses on RNAi therapeutics for diseases like thromboembolic conditions and retinal diseases.

Original reporting
rttnews.com
Published Oct 16, 2026, 3:36 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 16, 2026, 3:42 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefIPO
Primary signal
$CTY
Bullish
high confidence
Mentioned
$CTY
Relevance
8/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$CTYBullishHigh
01

Why it matters

The $200 million capital raise provides runway for its pipeline and signals market confidence.

02

Market read

First report of City Therapeutics' IPO pricing; creates immediate trading interest for the debut.

03

What to watch

Potential regulatory hurdles for RNAi therapies could temper enthusiasm despite strong raise.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

City Therapeutics is a clinical‑stage RNAi biotech preparing its Nasdaq debut.

Company-level read

Ticker impact

$CTYBullishHigh confidence
Context

City Therapeutics priced an upsized $200 million IPO at $18 per share, set to debut on Nasdaq.

Expected impact

potential upward pressure as the stock opens, driven by fresh capital inflow and market interest

Evidence & confidence

New primary disclosure of a sizable biotech raise; first report of pricing creates immediate trading opportunity.

Market effects

Sector

Adds to biotech IPO pipeline, may boost sector sentiment and peer valuations.

Regional

U.S. biotech market sees fresh capital, could attract further investor allocations.

Global

Limited to U.S. markets; modest global effect beyond biotech investors.

Counterpoint

What could challenge this read

If the IPO is oversubscribed, pricing may be too aggressive, leading to a post‑launch sell‑off.

Key entities

  • underwriter
    Goldman Sachs & Co. LLC

    Joint book‑running manager for the IPO.

  • underwriter
    Jefferies

    Joint book‑running manager for the IPO.

  • underwriter
    Stifel

    Joint book‑running manager for the IPO.

Read at source← All news

StoryCity Therapeutics upsizes IPO, pricing 11.1 M shares at $18 each

Also covered by

3 outlets

Related articles

OCT 16
$CTYHighAI 9/10

City Therapeutics, Inc. Prices Upsized $200M IPO at $18

City Therapeutics priced an upsized IPO of 11.1M shares at $18 each, raising $200M. Shares will begin trading on Nasdaq as CTY on Oct. 16, 2026, subject to conditions. The company has no prior public trading history and plans to use proceeds for its clinical-stage RNAi pipeline.

tradingview.com1 min
OCT 9
$CTYHighAI 8/10

City Therapeutics IPO: RNAi biotech seeks up to $185 million

City Therapeutics, a biotech developing RNAi drugs, filed for an IPO seeking up to $184.7M, offering 9.7M shares at $17-$19 each. The company plans to list on Nasdaq under CTY. Its lead candidate, CITY-FXI, showed promising Phase 1 trial results. The company has raised $238.8M in equity and reported a $53.4M net loss for H1 2026. Proceeds will fund clinical development and research. (350 characters)

finance.yahoo.com2 min
OCT 16
$IAMHighAI 9/10

Iambic Therapeutics IPO Raises $150M, Stock Jumps

Iambic Therapeutics (IAM) raised $150M in its IPO, priced at $16, and saw shares jump 18% to close at $18.91. The company, which uses AI for drug discovery, has partnerships with AbbVie, Takeda, and Nvidia. It reported $12.8M revenue and a $50.1M net loss for H1 2026. Proceeds will fund oncology programs.

briefs.co2 min